Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STIM1 | Q13586 | 2/20 | 0.62 |
| ▸ | ORAI1 | Q96D31 | 2/20 | 0.62 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.62 |
| ▸ | EPHX2 | P34913 | 11/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.46 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.46 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.46 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | STAT3 | P40763 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL758805 | 0.91 | STIM1 (0.53) | STIM1ORAI1ORAI3EPHX2KDM4E | |
| SCHEMBL758944 | 0.91 | STIM1 (0.76) | STIM1ORAI1ORAI3EPHX2KDM4E | |
| SCHEMBL758399 | 0.89 | STIM1 (0.60) | STIM1ORAI1ORAI3CACNA1GCACNA1H | |
| SCHEMBL757151 | 0.87 | STIM1 (0.67) | STIM1ORAI1ORAI3KDM4ECACNA1G | |
| SCHEMBL761267 | 0.85 | STIM1 (0.49) | STIM1ORAI1ORAI3EPHX2KDM4E | |
| SCHEMBL759168 | 0.85 | STIM1 (0.65) | STIM1ORAI1ORAI3CACNA1GCACNA1H | |
| SCHEMBL755784 | 0.84 | STIM1 (0.61) | STIM1ORAI1ORAI3EPHX2CACNA1G | |
| SCHEMBL760682 | 0.84 | STIM1 (0.54) | STIM1ORAI1ORAI3EPHX2KDM4E | |
| SCHEMBL757534 | 0.84 | STIM1 (0.62) | STIM1ORAI1ORAI3EPHX2CACNA1G | |
| SCHEMBL696552 | 0.84 | SMN1; SMN2 (0.53) | STIM1ORAI1ORAI3EPHX2KLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399436-B2 | N-pyrazolyl carboxamides as CRAC channel inhibitors | GLAXO GROUP LIMITED (GB) | 2013-03-19 | — | — | US | disclosed |
| US-8399436-B2 | N-pyrazolyl carboxamides as CRAC channel inhibitors | GLAXO GROUP LIMITED (GB) | 2013-03-19 | — | — | US | disclosed |
| US-20120053150-A1 | N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INIHIBITORS | GLAXO GROUP LIMITED (GB) | 2012-03-01 | — | — | US | disclosed |
| US-20120053150-A1 | N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INIHIBITORS | GLAXO GROUP LIMITED (GB) | 2012-03-01 | — | — | US | disclosed |
| WO-2010122089-A1 | N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INHIBITORS | GLAXO GROUP LIMITED (GB) | 2010-10-28 | — | — | WO | disclosed |
| US-20100273744-A1 | COMPOUNDS | GORE PAUL MARTIN | 2010-10-28 | — | — | US | disclosed |
| US-20100273744-A1 | COMPOUNDS | GORE PAUL MARTIN | 2010-10-28 | — | — | US | disclosed |
| US-20100273744-A1 | COMPOUNDS | GORE PAUL MARTIN | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053150-A1 | N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INIHIBITORS | ORAI1, TRPV1, CACNA1E | STIM1 33/4885ORAI1 1/4885ORAI3 25/4885 |
| US-20100273744-A1 | COMPOUNDS | LTC4S, HRH4, HRH2 | STIM1 2564/4885ORAI1 3127/4885ORAI3 2440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.